Section

Industry Orgs Applaud Bill to Boost Bars, Restaurants and Venues with Draft Systems

Retrieved on: 
Monday, March 11, 2024

The CHEERS Act would provide a tax deduction for bars, restaurants and entertainment venues with draft beer systems to help revitalize hospitality establishments still struggling years after the pandemic.

Key Points: 
  • The CHEERS Act would provide a tax deduction for bars, restaurants and entertainment venues with draft beer systems to help revitalize hospitality establishments still struggling years after the pandemic.
  • This bipartisan bill will support these local establishments by incentivizing the expansion of tap lines and keg equipment on commercial premises.
  • “The CHEERS Act would boost not only our smaller bars, clubs and entertainment venues but also many of our casinos, hotels and arenas.
  • And we will reduce waste created by using smaller, disposable containers at many restaurants, bars and other venues.

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.

Guggenheim Investments Announces March 2024 Closed-End Fund Distributions

Retrieved on: 
Friday, March 1, 2024

Final determination of the character of distributions will be made at year-end.

Key Points: 
  • Final determination of the character of distributions will be made at year-end.
  • Distributions may be paid from sources of income other than ordinary income, such as short-term capital gains, long-term capital gains or return of capital.
  • Unless otherwise noted, the distributions above are not anticipated to include a return of capital.
  • The final determination of the source and tax characteristics of all distributions will be made after the end of the year.

Grupo Aeroportuario Del Pacifico Announces Annual General Ordinary And Extraordinary Shareholders’ Meeting

Retrieved on: 
Thursday, February 29, 2024

GUADALAJARA, Mexico, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B.

Key Points: 
  • GUADALAJARA, Mexico, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B.
  • de C.V. invites its shareholders to the General Ordinary and General Extraordinary Shareholders’ Meeting on April 25, 2024 at 12:00 and 2:00 pm, respectively, in Salon Midtown Ballroom 3, 3rd floor of the Hilton Hotel, located at Av.
  • V. Cancellation of any amounts outstanding under the share repurchase program approved at the Annual General Ordinary Shareholders’ Meeting that took place on April 13, 2023, which amounts to Ps.
  • The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors.

Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of Inaugural ROP Awareness Week, Feb. 26 - March 3, 2024

Retrieved on: 
Wednesday, February 21, 2024

CHICAGO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has launched the new "Retinopathy of Prematurity Education and Support Program," as part of its first ROP Awareness Week, declared Feb. 26 – March 3, 2024. The group is offering a variety of free educational resources to the public and professionals, including fact sheets, social media graphics in English and Spanish, dedicated online resources, and a new video series.

Key Points: 
  • "Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss," said Jeff Todd, president and CEO of Prevent Blindness.
  • To help address the need for ROP awareness and education, Prevent Blindness convened leading organizations in the parent support, education, and advocacy arenas to partner on creating the ROP Education and Support Program.
  • The ROP Education and Support Program and ROP Awareness Week is supported by funding from Regeneron .
  • In the Prevent Blindness Focus on Eye Health Expert Series, " Retinopathy of Prematurity ," Jeff Todd, president and CEO of Prevent Blindness, interviews R.V.

Farmland Partners Announces Tax Treatment of 2023 Distributions

Retrieved on: 
Tuesday, February 13, 2024

The special dividend of $0.21 per share declared in December for shareholders of record as of December 29, 2023, and paid on or around January 12, 2024, is a split-year distribution with $0.17 per share considered a distribution made in 2023 for federal income tax purposes1.

Key Points: 
  • The special dividend of $0.21 per share declared in December for shareholders of record as of December 29, 2023, and paid on or around January 12, 2024, is a split-year distribution with $0.17 per share considered a distribution made in 2023 for federal income tax purposes1.
  • In 2023, there was no “Box 3 Nondividend Distribution” on form 1099-DIV, and therefore no requirement to file Form 8937.
  • The Nareit REIT 1099-DIV Spreadsheet is available for download under the heading “2023 Dividend Information” at this link: https://ir.farmlandpartners.com/resources/IRS-Forms/default.aspx .
  • Stockholders are encouraged to consult with their tax advisors as to the specific tax treatment of the distributions they received from us.

Demographics, labor market power and the spatial equilibrium

Retrieved on: 
Tuesday, February 13, 2024

Abstract

Key Points: 
    • Abstract
      This paper studies how demographics affect aggregate labor market power, the urban wage
      premium and the spatial concentration of population.
    • I develop a quantitative spatial model
      in which labor market competitiveness depends on the demographic composition of the local
      workforce.
    • If these factors differ across workers, labor market power has a role to
      play in explaining wage inequality.
    • This paper contributes to the literature on differences in labor market power by analyzing a
      new dimension of heterogeneity: demographics.
    • Since older workers are less mobile in terms of
      switching workplaces, firms have more labor market power over older workers.
    • I start by estimating labor market power by measuring the sensitivity of worker turnover to
      the wage paid.
    • I find a strong
      role of demographics in determining the degree of labor market power enjoyed by firms.
    • Next, I provide evidence of the importance of differences in labor market power for spatial
      wage inequality.
    • To explore the consequences of labor market sorting, I build a spatial general equilibrium
      model in which labor market competitiveness depends on the demographic composition of the

      ECB Working Paper Series No 2906

      2

      local workforce.

    • If these factors differ across workers, labor market power has a role to
      play in explaining wage inequality.
    • In
      the model, geographic sorting by age matters and leads to higher labor market power in rural
      areas, which implies an urban wage premium that is 4% larger than with uniform labor supply
      elasticities.
    • I follow Manning (2013) and estimate labor market power by measuring the sensitivity of worker
      turnover to the wage paid.
    • Bachmann et al., 2021; Ahlfeldt et al., 2022a; Berger et al.,
      2022) that nest a monopsonistic labor market in a spatial general equilibrium model (Redding
      and Rossi-Hansberg, 2017).
    • As firms have more labor market power
      over older workers, they face an upward-sloping labor supply curve that is less elastic in regions
      with an older workforce.
    • Firms choose in which labor market to operate in the sense that there is free
      entry at fixed costs into all locations.
    • How are differences in labor market competitiveness across space sustained in spatial equilibrium?
    • I use the model to quantify the importance of heterogeneity
      in labor market power for the urban wage premium and the spatial concentration of population.
    • My work is complementary to but quite different
      from this paper since I argue that population aging increases labor market power rather than
      product market power.
    • By analyzing the effects of a changing age composition of the workforce in the context
      of labor market power, I relate to literature on the labor market effects of population aging.
    • ECB Working Paper Series No 2906

      7

      after controlling for age, differences in labor market power between East and West Germany
      vanish.

    • They conclude that higher
      concentration is associated with higher labor market power (as in the model of Jarosch et al.,
      forthcoming).
    • I offer an alternative explanation why labor market power differs across regions:
      Since denser regions have a younger workforce, workers are more mobile in terms of switching
      jobs which implies lower labor market power of firms.
    • In this case, I infer a
      high labor supply elasticity and low labor market power of firms.
    • I contribute to this growing debate by
      quantifying differences in labor market power across worker groups and their effects on regional
      inequality.
    • While the model shows how demographics affect labor market power, the urban wage premium and agglomeration, one fundamental question remains open for future research: What
      are the policy implications of (differences in) labor market power?

NEVADA KING INTERCEPTS 3.52 G/T AU OVER 61.0M AND 6.05 G/T AU OVER 41.1M INCLUDING 19.44 G/T AU OVER 7.6M, EXTENDS OXIDE MINERALIZATION 300M NORTHWEST OF THE ATLANTA PIT

Retrieved on: 
Monday, February 12, 2024

AT23WS-62 intercepted 6.05 g/t Au over 41.1m including 19.44 g/t Au over 7.6m and was drilled approximately 300m northwest of the Atlanta Pit approximately 8m west of historical RC hole DHRI-12-MRC1 (1.95g/t Au over 77.8m), which did not completely penetrate the mineralized zone.

Key Points: 
  • AT23WS-62 intercepted 6.05 g/t Au over 41.1m including 19.44 g/t Au over 7.6m and was drilled approximately 300m northwest of the Atlanta Pit approximately 8m west of historical RC hole DHRI-12-MRC1 (1.95g/t Au over 77.8m), which did not completely penetrate the mineralized zone.
  • AT23WS-62 did fully penetrate the mineralized zone and returned an average grade three times greater than DHRI-12-MRC1.
  • Referring to Figure 2, AT23WS-62 drilled across a high-angle structure into an adjacent mineralized block, which accounts for the shorter intercept length when compared to DHRI-12-MRC1.
  • As we continue testing for similar mineralization along lines north and south of Section 22-16N(2), good potential exists for building tonnage.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
Monday, February 12, 2024

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
Monday, February 12, 2024

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.